<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942615</url>
  </required_header>
  <id_info>
    <org_study_id>Cardio-RT</org_study_id>
    <nct_id>NCT02942615</nct_id>
  </id_info>
  <brief_title>The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.</brief_title>
  <official_title>A Randomized Multi-center Phase III Study About the Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Under the modern precise radiotherapy technology, clear the best dose volume limit index and
      the limit value for the primary level prevention of heart injury; clear best follow-up
      interval and measures for heart function of breast cancer patients, to achieve the secondary
      prevention of cardiac injury; explore combined cardiovascular specialist optimal treatment
      strategy for heart injury in the treatment of breast cancer, during the tertiary prevention
      of cardiac injury; put forward rationalization proposal for prevention, treatment and
      follow-up for breast cancer associated with heart injury.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event free survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>event free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of value of serum cardiac biomarker</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of value of serum cardiac biomarker</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of left ventricular ejection fraction (LVEF)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of LVEF</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative change of LVEF</measure>
    <time_frame>10 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score of life quality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score of life quality</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Cardiotoxicity</condition>
  <arm_group>
    <arm_group_label>Heart safety management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>limit heart dose more frequent follow up of cardiac function professional management of cardiac toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>without any restrict heart dose limitation for RT Follow up of cardiac function Observation and without any special management of cardiac toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>limit heart dose</intervention_name>
    <description>limit heart dose: Dmean≤6Gy,V30≤20%,V10≤50%</description>
    <arm_group_label>Heart safety management</arm_group_label>
    <other_name>frequently follow of cardiac function</other_name>
    <other_name>management of cardiotoxicity</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients willing to participate the research and sign the informed consent file;

          -  Patients aged 18-80 years;

          -  KPS≥70;

          -  Pathological diagnosis for invasive breast cancer;

          -  Patients received anthracycline/paclitaxel based chemotherapy, or herceptin based
             targeted therapy;

          -  No functional heart disease;

          -  LVEF≥50%;

          -  Patients received breast conserving surgery;

          -  Patients received modified radical mastectomy: T1-2 with N1-3 or T3-4 with any N;

          -  Tumor margin negative;

          -  No metastases;

          -  No other malignant tumor history.

        Exclusion Criteria:

          -  Patients with metastases;

          -  Tumor margin positive;

          -  Patients received modified radical mastectomy with T1-2 and N0;

          -  Patients have other malignant tumor;

          -  Patients have a history of heart disease;

          -  Patients received chest radiotherapy previously;

          -  Patients with severe organic and functional disease;

          -  Unqualified patients with sufficient reasons;

          -  Cannot or no willing to sign the informed consent file;

          -  Patients with autoimmune disease;

          -  Women with pregnancy, planned pregnancy or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia-Yi Chen, M.D.</last_name>
    <phone>+86-021-64370045</phone>
    <phone_ext>602400</phone_ext>
    <email>chenjiayi0188@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia-Yi Chen, M.D.</last_name>
      <phone>+86-021-64370045</phone>
      <phone_ext>602400</phone_ext>
      <email>chenjiayi0188@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Jia-Yi Chen, M.D</last_name>
      <phone>+86-021-64370045</phone>
      <phone_ext>602400</phone_ext>
      <email>chenjiayi0188@aliyun.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Jiayi Chen</investigator_full_name>
    <investigator_title>Chief of department of radiation oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

